MAP4K
-
MAP4K Related Products (56)
Related Products (56)
-
MAP4K4-IN-6
0 ImagesCat. No.: HY-162922MAP4K4-IN-6 (Compound 15f) is a MAP4K4 inhibitor (IC50: 80 nM). MAP4K4-IN-6 reduces the c-Jun phosphorylation. MAP4K4-IN-6 has neuroprotective effects. MAP4K4-IN-6 increases the viability of motor neurons. MAP4K4-IN-6 can be used for research of Amyotrophic lateral sclerosis (ALS).
-
HPK1-IN-9
0 ImagesCat. No.: HY-145035CAS No.: 2734168-78-4HPK1-IN-9 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-9 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 112) .
-
HPK1-IN-38
0 ImagesCat. No.: HY-156509CAS No.: 2578802-72-7HPK1-IN-38 (compound 15) is a MAP4K1/HPK1 inhibitor，can be used for HPK1 related disorders research.
-
HPK1-IN-20
0 ImagesCat. No.: HY-145109CAS No.: 2561490-78-4HPK1-IN-20 (Compound 106) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor.
-
HPK1-IN-37
0 ImagesCat. No.: HY-156508CAS No.: 2766481-68-7HPK1-IN-37 (compound A85) is an inhibitor of HPK1 (IC50=3.7 nM). HPK1-IN-37 can be used for research in HPK1 related disorders or diseases including cancers.
-
BAY-405
0 ImagesCat. No.: HY-169199CAS No.: 2442532-66-1BAY-405 (compund 38) is a MAP4K1 inhibitor that exhibits nanomolar potency in biochemical and cellular assays and achieves in vivo exposure after oral administration.
-
HPK1-IN-30
0 ImagesCat. No.: HY-143871CAS No.: 2700292-56-2HPK1-IN-30 is a potent inhibitor of HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1-IN-30 has the potential for the research of cancer diseases (extracted from patent WO2021175271A1, compound 3).
-
HPK1-IN-42
0 ImagesCat. No.: HY-160218CAS No.: 2848684-50-2HPK1-IN-42 (compound 185) ia a HPK1 inhibitor with the IC50 50 of 0.24 nM.
-
Octahydrocurcumin (Standard)
0 ImagesSynonyms: Hexahydrobisdemethoxycurcumin (Standard)Octahydrocurcumin (Hexahydrobisdemethoxycurcumin) is a hydrogenated derivative of curcumin and a metabolite of curcumin. Octahydrocurcumin is an orally active anticancer and anti-inflammatory agent, and is the final hydrogenated metabolite of Curcumin (HY-N0005) in vivo. Octahydrocurcumin exerts its anti-tumor and anti-inflammatory effects by inducing the mitochondrial apoptosis pathway and inhibiting the TAK1-NF-κB-COX-2 pathway, respectively.
-
NG25 (Standard)
0 ImagesCat. No.: HY-15434RCAS No.: 1315355-93-1NG25 (Standard) is the analytical standard of NG25. This product is intended for research and analytical applications. NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC50s of 149 nM and 21.7 nM, respectively.
-
DMX-5804 (Standard)
0 ImagesCat. No.: HY-111754RCAS No.: 2306178-56-1DMX-5804 (Standard) is the analytical standard of DMX-5804 (HY-111754). This product is intended for research and analytical applications. DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96). DMX-5804 enhances cardiomyocyte survival, and reduces ischemia-reperfusion injury in mice.
-
NCB-0846 (Standard)
0 ImagesNCB-0846 (Standard) is the analytical standard of NCB-0846 (HY-100830). This product is intended for research and analytical applications. NCB-0846 is an orally active, selective inhibitor for Wnt, that inhibits Traf2- and Nck-interacting kinase (TNIK) with an IC50 of 21 nM. NCB-0846 blocks TGF-β signaling pathway by inhibiting SMAD2/3 phosphorylation and nuclear translocation.
-
GNE-495 (Standard)
0 ImagesCat. No.: HY-100343RCAS No.: 1449277-10-4
-
HPK1-IN-54
0 ImagesCat. No.: HY-159905CAS No.: 3048537-48-7HPK1-IN-54 is a potent HPK1 (Hematopoietic Progenitor Kinase 1) inhibitor that enhances T cell activation and proliferation by inhibiting HPK1 activity, thereby exhibiting antitumor effects. Its IC50 value against HPK1 is 2.67 nM, with excellent selectivity over the MAP4K family (>100-fold) and other selected kinases (>300-fold). HPK1-IN-54 displayed moderate in vivo clearance and reasonable oral exposure in mice and rats. Additionally, HPK1-IN-54 demonstrated strong antitumor efficacy in a CT26 murine colon cancer model and synergistic effects when combined with anti-PD-1 (HY-P9902A). HPK1-IN-54 shows promise for research in the field of immunotherapy.
